title: Cyclooxygenase-2 suppresses the anabolic response to PTH infusion in mice.
abstract: We previously reported that the ability of continuously elevated PTH to stimulate osteoblastic differentiation in bone marrow stromal cell cultures was abrogated by an osteoclastic factor secreted in response to cyclooxygenase-2 (Cox2)-produced prostaglandin E2. We now examine the impact of Cox2 (Ptgs2) knockout (KO) on the anabolic response to continuously elevated PTH in vivo. PTH (40 μg/kg/d) or vehicle was infused for 12 or 21 days in 3-mo-old male wild type (WT) and KO mice in the outbred CD-1 background. Changes in bone phenotype were assessed by bone mineral density (BMD), μCT and histomorphometry. PTH infusion for both 12 and 21 days increased femoral BMD in Cox2 KO mice and decreased BMD in WT mice. Femoral and vertebral trabecular bone volume fractions were increased in KO mice, but not in WT mice, by PTH infusion. In the femoral diaphysis, PTH infusion increased cortical area in Cox2 KO, but not WT, femurs. PTH infusion markedly increased trabecular bone formation rate in the femur, serum markers of bone formation, and expression of bone formation-related genes, growth factors, and Wnt target genes in KO mice relative to WT mice, and decreased gene expression of Wnt antagonists only in KO mice. In contrast to the differential effects of PTH on anabolic factors in WT and KO mice, PTH infusion increased serum markers of resorption, expression of resorption-related genes, and the percent bone surface covered by osteoclasts similarly in both WT and KO mice. We conclude that Cox2 inhibits the anabolic, but not the catabolic, effects of continuous PTH. These data suggest that the bone loss with continuously infused PTH in mice is due largely to suppression of bone formation and that this suppression is mediated by Cox2.
authors.affiliation: New England Musculoskeletal Institute, University of Connecticut Health Center, Farmington, Connecticut, United States of America; Department of Medicine, University of Connecticut Health Center, Farmington, Connecticut, United States of America.
authors.forename: Shilpa
authors.initials: S
authors.lastname: Choudhary
authors.affiliation: New England Musculoskeletal Institute, University of Connecticut Health Center, Farmington, Connecticut, United States of America.
authors.forename: Ernesto
authors.initials: E
authors.lastname: Canalis
authors.affiliation: New England Musculoskeletal Institute, University of Connecticut Health Center, Farmington, Connecticut, United States of America.
authors.forename: Thomas
authors.initials: T
authors.lastname: Estus
authors.affiliation: New England Musculoskeletal Institute, University of Connecticut Health Center, Farmington, Connecticut, United States of America.
authors.forename: Douglas
authors.initials: D
authors.lastname: Adams
authors.affiliation: New England Musculoskeletal Institute, University of Connecticut Health Center, Farmington, Connecticut, United States of America; Department of Medicine, University of Connecticut Health Center, Farmington, Connecticut, United States of America.
authors.forename: Carol
authors.initials: C
authors.lastname: Pilbeam
mesh_terms: D000818:Animals; D015519:Bone Density / Q000187:drug effects*; D051546:Cyclooxygenase 2 / Q000235:genetics / Q000378:metabolism*; D005269:Femur / Q000378:metabolism*; D008297:Male; D051379:Mice; D018345:Mice, Knockout; D010012:Osteogenesis / Q000187:drug effects*; D010281:Parathyroid Hormone / Q000494:pharmacology*; D013131:Spine / Q000378:metabolism*
chemical_list: D010281:Parathyroid Hormone; C077623:Ptgs2 protein, mouse; D051546:Cyclooxygenase 2